Tuesday, 29 September 2026Updated 8m ago
Litmus Paper

Indian business & markets · every report, clustered into stories and tested for tone

NSE close · Mon, 28 SeptNifty 5022,780.25▼ 1.56%Nifty Bank54,471.65▼ 1.99%Midcap 10059,914.20▼ 1.63%Smallcap 25017,863.20▼ 1.63%India VIX13.64▲ 12.17%IT28,086.50▼ 0.26%Auto26,525.05▼ 1.64%Pharma26,761.65▼ 0.89%FMCG45,264.35▼ 1.47%Metal12,854.40▼ 1.78%Realty850.90▼ 2.12%Energy36,693.20▼ 2.00%PSU Bank8,026.10▼ 3.24%Financials24,671.65▼ 1.69%Media1,539.25▼ 0.74%Defence9,231.20▼ 1.81%Durables38,162.90▼ 0.30%Biggest movesRSYSTEMS▲ 16.8%REPRO▲ 15.8%DAMCAPITAL▲ 14.8%SMCGLOBAL▲ 13.6%BPLPHARMA▲ 13.3%PRIMO▲ 11.3%SSDL▲ 11.2%SYNCOMF▲ 10.7%

Top stories

Lerodalcibep · 2 storiesClear filters
Developing 158Picking up 28Price moves 58Following
Busiest tags today
Global markets143Market valuations142AI140Crude oil137Nifty and Sensex105Geopolitics101Bond yields79Iran76Banks70Trade and tariffs54Gold54US Treasuries54Wall Street47Listing rules44Every tag in Market pulse →
Topic
Lerodalcibep▲ +100% net tone today
2 stories today · 2 since 28 SeptSun Pharma −0.8% on Mon, 28 Sept
Often with, this weekPharma and healthcare2Sun Pharma2China1
Open tag page →Clear ×
Stories per day
Deal▲

Sun Pharma secures rights to commercialise Lerodalcibep outside the US and China

  • Sun Pharma will commercialise and manufacture Lerodalcibep worldwide, excluding the United States and China
  • The once-monthly PCSK9 inhibitor treats adults with high LDL cholesterol
  • LIB Therapeutics will receive upfront and milestone payments plus royalties on net sales
  • The licensing deal expands Sun Pharma’s cardiovascular pipeline and potential sales beyond the US and China
Sun Pharma−0.8%LerodalcibepPharma and healthcareChina8 sources · 12h
That’s everything for today